Almac Pod
Craigavon, N.I., UK, October 16, 2017-
Almac Group
, the global contract development and manufacturing organization, has recognized the need for a change in dynamics of temperature controlled shipping with the launch of its new
Almac Pod
™ service solution in the United States. Understanding the cost, logistical, and compliance challenges posed by this changing environment, the Almac Pod was originally released in Europe and serves as a first-to-market service solution. The innovative solution incorporates the efficiencies of the Almac-approved, global courier network and advanced phase change material technology (PCM) to create a temperature-controlled shipping service solution that eases the burden for its global clinical supply customers. The Almac Pod offers a Protected, Optimized and Dynamic solution which safeguards customers’ products and mitigates against temperature excursions of all clinical shipments-the perfect solution for biologics or difficult to handle products. Since launching the service, the Almac Pod has been 100% effective in protecting the integrity of shipped products with no known temperature excursions within the shipper qualification period. Leon Supplee, Director of Logistics, Almac Clinical Services, commented: “On the cusp of our success launching the Almac Pod in Europe, we have expanded our new temperature-controlled shipping service solution to the United States and internationally. Our customers continuously need a solution to keep pace with rapidly growing demand for controlled temperature shipments. With increased volume, the Almac Pod allows us to build on our streamlined clinical trial supply chain. The service has equipped us, and our clients, to work seamlessly across the logistics process by protecting temperature controlled products and compares more effectively than traditional water-based solutions. The Almac Pod is fully GDP-compliant and is available as part of Almac’s end-to-end, global supply chain management solution-your product, safe in our hands.” For further details on the Almac Pod, download the whitepaper: Changing the Dynamics of Temperature Controlled ShippingSolutions
here
. About Almac Group ‘Partnering to Advance Human Health’ The Almac Group is a contract development and manufacturing organization that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery development and commercialization, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture. The international company is a privately owned organization that has organically grown over almost 50 years and now employs in excess of 5,000 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations in the UK, Ireland, across the US (Pennsylvania, North Carolina and California), and in Asia (Singapore and Tokyo). To keep up to date with our latest releases, follow us on
and
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.